

Patient Information	Specimen Information	Client Information

Cardio IQ®

Test Name	Current		Risk/Reference Interval			Units	Historical	
	Result & Risk		Optimal	Moderate	High		Result & Risk	
	Optimal	Non-Optimal						
METABOLIC MARKERS								
TMAO (Trimethylamine N-oxide)	5.4		<6.2	6.2-9.9	>=10.0	uM		

For details on reference ranges please refer to the reference range/comment section of the report.

SPECIMEN:

Patient Information	Specimen Information	Client Information

Reference Range/Comments

Analyte Name	In Range	Out Range	Reference Range	Lab
TMAO (TRIMETHYLAMINE N OXIDE)	5.4		<6.2 uM	
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Based on a population (N=4007) defined as ambulatory stable patients without acute coronary syndrome who underwent elective diagnostic coronary angiography (1) and a reference range study of apparently healthy donors (N=180), we have defined the following cut-offs for TMAO to assess relative risk of a cardiovascular event: A cut-off of <6.2 uM defines a population at optimal relative risk for a cardiovascular event relative to those above this level. 6.2-9.9 uM defines a population at moderate relative risk for a cardiovascular event (two-fold increased risk of MACE at 3 years) relative to those with TMAO <6.2 uM (1). Given the dose-dependent relationship between TMAO and cardiovascular event risk demonstrated across multiple clinical subgroups (2), those above the upper limit of the Cleveland HeartLab 95% population interval (>=10.0 uM) are defined as high relative risk for a cardiovascular event relative to those with TMAO <6.2 uM. (References: 1-Tang et al. N Engl J Med. 2013; 368:1575-1584. 2-Heianza Y, et al. J Am Heart Assoc. 2017;6(7)).				

SPECIMEN: